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Summary
Inflammatory breast cancer (IBC) is the most deadly form of breast cancer in humans presumably due to its
ability to metastasize from its inception. In our laboratory, overexpression of RhoC GTPase was observed to be
specific for IBC tumors, but not for stage-matched, non-IBC tumors. RhoC is known to contribute to an IBC-like
phenotype in HPV-E6E7 immortalized breast cells. To further study the effect of RhoC overexpression on IBC
metastasis, we generated stable transfectants of spontaneous immortalized mammary epithelial cells (MCF10A)
overexpressing wild-type RhoC or a constitutively active RhoC mutant (G14V). Both the RhoC wild type and the
G14V transfectants were highly invasive and proliferated more rapidly compared to vector-only control clones.
Overexpression of RhoC led to an increase in actin stress fiber and focal adhesion contact formation. Comparative
microarray analysis of these clones further revealed that RhoC overexpression upregulated 108 genes whereas
seven genes were down-regulated. We have further verified by quantitative RT-PCR that genes involved in cell
proliferation, invasion/adhesion, and angiogenesis were modulated by RhoC. This work suggests strong candidates
for the downstream oncogenic functions of RhoC.
Abbreviations: CXCL1: CXC chemokine ligand 1; EGF: epidermal growth factor; GAPDH: glyceraldehyde-3-
phosphate dehydrogenase; GEF: guanine nucleotide exchange factor; HA: influenza virus hemagglutinin epitope;
HPV: human papilloma virus; IBC: inflammatory breast cancer; IGF: insulin-like growth factor; IGF-BP: IGF-
binding protein; RT-PCR: reverse transcriptase-PCR; TGF-β: transforming growth factor-β; VEGF: vascular
endothelial growth factor; WT: wild-type
Introduction
Primary IBC is the most lethal form of breast cancer
and accounts for approximately 6% of new breast can-
cer cases annually in the United States [1, 2]. IBC
is clinically well characterized by a very rapid on-
set of skin changes such as erythema, skin nodules,
dimpling of the skin (termed ‘peau d’aurange’), and
nipple retraction, typically within six months [1–4].
IBC cells acquire metastatic capabilities early in tu-
mor formation; nearly all women with IBC have
tumor emboli that are present in the dermal lym-
phatics at the time of diagnosis, and over one-third
have distant metastases [3, 4]. In spite of mod-
ern multimodality treatments, the 5-year disease-free
survival is less than 45%, thus making IBC the
most deadly form of locally advanced breast cancer
[3, 4].
In our laboratory, we sought to identify the genetic
basis of IBC development and progression [5]. Over-
expression of RhoC GTPase [6] and down-regulation
of WISP3 [7] are characteristic and specific for IBC,
in work performed on SUM149, an IBC cell line [8].
Moreover, overexpression of RhoC GTPase was iden-
tified in 90% of IBC archival tumor samples, but not
in stage III non-IBC tumors [5].
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RhoC belongs to the Ras superfamily of small
GTPase, which includes RhoA and RhoB (homolo-
gous to RhoC) as well as many others, including Rac
and Cdc42 [9]. Upregulation of RhoC plays important
roles in metastasis not only in IBC, but also in a pleth-
ora of malignant neoplasms including bladder [10],
ovary [11], pancreas [12], and skin (melanoma) [13].
However, RhoC signaling and its downstream molecu-
lar targets involved in IBC progression are still poorly
understood.
In order to gain further insight into RhoC down-
stream signaling, we have developed breast-specific
cellular reagents that would allow us to study the gene
expression changes caused by RhoC upregulation.
Stable transfectants of wild-type RhoC (RhoC-WT)
and a constitutively active RhoC mutant (G14V) were
generated in human mammary epithelial cells. We
performed oligonucleotide/cDNA microarray compar-
ative analysis of these clones and vector-only trans-
fectants. Our laboratory had previously established
stable wild-type RhoC transfectants in HPV-E6/E7 im-
mortalized human mammary epithelial cells (termed
HME-E6/E7), which acquired an aggressive IBC-like
phenotype, including high motility and invasiveness,
ability to grow on soft agar, and ability to form tumors
in nude mice [6].
For studies of gene expression changes, we aimed
to develop cellular reagents that isolated RhoC over-
expression as a genetic event, independent of viral
immortalization of the parental cell line. In this study,
we employed RhoC constructs (Guthrie cDNA Re-
source Center) which comprise only the coding region
of RhoC with three HA-tags at the N-terminus in
pcDNA3.1 (Invitrogen, Carlsbad, CA). To avoid po-
tential phenotype changes associated with immortali-
zation, we used MCF10A cells as the parental
substrate. MCF10A was derived from the proliferative
epithelium of a fibrocystic lesion [14]. Importantly,
biological assays showed that the MCF10A-RhoC WT
and the G14V transfectants exhibited enhanced inva-
sion and cell proliferation quantitatively comparable
to the original HME E6/E7 clones. The formation
of stress fibers and focal adhesion in these cells was
significantly increased, which is also characteristic in
cells overexpressing Rho family proteins [9], further
supporting that over-expression of RhoC morpholog-
ically transformed MCF10A cells.
Overall, the array analysis of our wild-type/G14V
RhoC clones lends strong support for a role of RhoC
in invasion and metastasis. The data showed increased
expression in 105 genes, and decreased expression in
seven genes. We confirmed RhoC-induced differen-
tial expression in several genes using RT-PCR. Here
we present the first summary data of genome-wide
expression changes induced by RhoC overexpression-
mediated transformation of breast cells.
Materials and methods
Cell culture
MCF10A cells [14] were cultured in 1:1 mixture of
Ham’s F12 (Mediatech, Herndon, VA) and DMEM
containing L-glutamine (Invitrogen, Carlsbad, CA),
supplemented with 5% horse serum (Invitrogen,
Carlsbad, CA), EGF, cholera toxin, insulin, hydro-
cortisone (Sigma, St. Louis, MO) at 37◦C under 10%
CO2. MCF10A cells are cytokeratin positive luminal
cells, which correlates with the histologic type of
the IBC SUM149 [15]. MCF10A cells were trans-
fected with either pcDNA3.1 (Invitrogen, Carlsbad,
CA), pcDNA3.1-RhoC wildtype or with pcDNA3.1-
RhoC constitutively active G14V mutant (Guthrie
cDNA Resource Center, http://www.cdna.org), us-
ing FuGene 6 (Roche Applied Science, Indianapolis,
IN). Stable transfectants were developed as previously
described [6] and maintained in the medium supple-
mented with 600 µg/ml G418 (Invitrogen, Carlsbad,
CA).
Western analysis
Cells were washed in ice-cold phosphate-buffered sa-
line, lysed in lysis buffer (10% glycerol, 50 mM Tris
pH 7.4, 100 mM NaCl, 1% NP-40, 2 mM MgCl2,
1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM PMSF)
on ice for 5 min, and then centrifuged for 5 min at 4◦C.
Cleared lysates (50 µg of protein each) were subjected
to SDS-PAGE and transferred to PVDF membrane.
Western blots were performed as described [16] us-
ing the anti-RhoC rabbit polyclonal antibody [16], the
anti-HA monoclonal antibody (Covance, Princeton,
NJ) and anti-β-actin goat antibody (Sigma, St. Louis,
MO) at dilutions of 1:1500, 1:1200 and 1:2000, re-
spectively.
Quantitative RT-PCR
Total messenger RNA was isolated using Trizol re-
agent (Invitrogen, Carlsbad, CA) per the manufac-
turer’s instruction. One microgram of total RNA was
converted to cDNA using an avian myeloblastosis
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virus reverse transcription system (Promega, Madison,
WI). A 100-mg aliquot of the resulting cDNA was
amplified in a double PCR with 25 ng each of
HA/GAPDH-specific primers or with the sequence-
specific primers for the genes of interest. PCR
products were separated on a 1.2% agarose gel and
imaged on an Alpha Image 950 documentation system
(Alpha Innotech, San Leandro, CA). Densitometry of
the images was performed using AlphaEaseFC (Alpha
Innotech, San Leandro, CA).
Cell staining of HA-tagged RhoC
and rhodamine-phalloidin
Cells were grown on chamber slides for 24 h and
washed with PBS followed by fixation with 3% par-
aformaldehyde in PBS for 10 min. After incubating in
0.1% Triton and blocking in 1% BSA, 2 Units of meth-
anolic rhodamine-phalloidin stock (Molecular Probes,
Eugene, OR) or 1:1000 dilution of the anti-HA mono-
clonal antibody (Covance, Princeton, NJ) in 200 µl
PBS were added to each coverslip and allowed to stain
for 1 h at room temperature. The samples containing
anti-HA were further stained with 1:400 dilution of
Alexa Fluor 488-conjugated anti-mouse secondary an-
tibody (Molecular Probes, Eugene, OR). All the slides
were mounted by Gel/Mount (Biomedia Co., Foster
City, CA). Cells were visualized under an Olympus
fluorescence microscope.
Monolayer growth rate
Monolayer culture growth rate was determined by
conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (Sigma, St. Louis, MO)
to a water-insoluble formazan by viable cells. Five-
hundred cells in 200 ml of medium were plated in
96-well plates and grown under normal conditions.
Cultures were assayed at 1, 3, 5, 7, 9, and 11 days
by adding 40 ml of 5 mg/ml MTT and incubating for
1 h at 37◦C. The medium was aspirated and 100 ml of
DMSO (Sigma, St. Louis, MO) were added to lyse the
cells and solubilized the formazan. Absorbance val-
ues of the lysates were determined on a Dynatech MR
5000 microplate reader at 595 nm.
Quantitative invasion assay
of the stable transfectants
Invasion assays were performed on 24-well culture
dishes per manufacturer’s instructions (Chemicon In-
ternational, Temecula, CA). The inserts within each
dish are equipped with a polycarbonate membrane
on the bottom coated with a thin layer of extracellu-
lar matrix (ECM) proteins. In brief, the inserts were
rehydrated in serum-free media. Cells were washed
in PBS and resuspended in serum-free medium at a
concentration of 5 × 105 cells/ml and 0.5 ml of cell
suspension was added to the insert. Wells in the culture
dish were filled with serum-containing medium. The
dish was incubated for 24 h at 37◦C in a 10% CO2
incubator. The cell suspension was aspirated and non-
invasive cells were removed from the insert using a
cotton swab. The inserts were stained with the staining
solution for 20 min, then rinsed in water. Stained cells
were dissolved in 10% acetic acid, and measured OD
at 595 nm.
Microarray procedures
DNA microarray analysis of gene expression was car-
ried out as previously described [17]. Briefly, purified
PCR products, generated using clone inserts (se-
quence verified Human cDNA clones from ResGen,
Carlsbad, CA) as template, were spotted onto poly-
L-lysine coated microscope slides using an Omni-
grid robotic arrayer (GeneMachines, San Carlos, CA)
equipped with quill-type pins (Majer Precision En-
gineering, Tempe, AZ) to generate 20,000 element
human cDNA microarrays. Protocols for printing and
post-processing of arrays are available in the public
domain [18].
Isolation of RNA, labeling of cDNA probes
and hybridization to cDNA arrays
Approximately 4–6 million cells per 100-mm tissue
culture plate were harvested in Trizol (Invitrogen,
Carlsbad, CA) and total RNA was isolated ac-
cording to the manufacturer’s protocol. An extra
phenol–chloroform extraction was performed to im-
prove the quality of RNA for microarray analyses.
Total RNA was quantified, RNA integrity adjusted by
denaturing-formaldehyde agarose gel electrophoresis,
and stored in aliquots at −80◦C until ready to use.
Forty micrograms of total RNA was routinely used
as template for cDNA generation using reverse tran-
scriptase (RT) (Invitrogen, Carlsbad, CA). Inclusion
of amino allyl-dUTP (Sigma, St. Louis, MO) in
the RT reaction allowed for subsequent fluorescent
labeling of cDNA using mono-functional NHS es-
ter dyes (Amersham Biosciences, Piscataway, NJ) as
described [18]. For every hybridization, fluorescent
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cDNA probes were prepared from RNA from RhoC-
transfected cells (coupled to Cy5 NHS-ester) and
matched vector transfected reference cells (coupled to
Cy3 NHS-ester). The labeled probes were then hybrid-
ized to the 20 K human cDNA microarrays at 65◦C
overnight as described [18]. Fluorescent images of hy-
bridized microarrays were obtained using a GenePix




of MCF10A-RhoC/G14V overexpressing clones
In order to isolate the MCF10A-RhoC-WT/G14V
stable transfectants, quantitative RT-PCR and west-
ern analysis were conducted. Using primers specifi-
cally designed to amplify HA tags and their junction
with RhoC, RT-PCR revealed a 5-fold increase in
HA-RhoC mRNA in the MCF10A-RhoC transfectants
(Figure 1(A)). The levels of RhoC expression corre-
lated well with those of the primary SUM149 cell line
and the previously described HME-RhoC transfect-
ants [5, 6]. Western analysis further confirmed that
the RhoC protein levels in the MCF10A-RhoC cells
are approximately two-fold higher than in the vector-
only controls (Figure 1(B)). For further verification,
we also tested HA-RhoC protein levels and protein
localization in the transfectants using immunofluo-
rescence staining (Figure 2, HA MoAb). As expec-
ted, the MCF10A-RhoC clones stained very strongly
with a monoclonal antibody against HA compared to
the vector only control. Based on the RT-PCR and
western analysis, we selected two clones each for
both MCF10A-RhoC WT and MCF10A-G14V for our
subsequent studies.
Overexpression of RhoC in MCF10A-RhoC
increased stress fiber formation, monolayer
growth rates, and invasion
The most prominent function of the Rho family pro-
teins is to induce the assembly of actin and myosin
filaments (stress fibers), to enhance focal adhesions,
and to act collaboratively with Rac and Cdc42 in cell
movement [9]. RhoC overexpression in HME E6/E7 is
known to enhance formation of stress fibers [6]. In our
new MCF10A-RhoC WT transfectants, we have like-
wise observed significant induction of the assembly
Figure 1. Expression of HA-RhoC in MCF10A-RhoC clones.
(A) Quantitative RT-PCR was performed on mRNA extracts
using primers specific for the HA-RhoC fusion gene, and
GAPDH (control). MCF10A breast cells stably transfected with
pcDNA3.1 (vector-only), pcDNA3.1-HA-RhoC WT (RhoC-WT)
or pcDNA3.1-HA-RhoC G14V (RhoC-G14V). (B) RhoC pro-
tein expression was confirmed by western analysis using the
anti-HA monoclonal antibody and the anti-RhoC polyclonal an-
tibody. Cleared lysates (50 µg of protein each) were subjected
to SDS-PAGE and transferred to PVDF membrane for western
analysis. The protein levels of β-actin were used as loading controls.
of actin filaments, using rhodamine-phalloidin to spe-
cifically stain F-actin (Figure 2). The control cells
were round and small; on the other hand, the RhoC
WT cells stretched in polygonal shapes and formed
multiple focal adhesion points (Figure 2).
The HME-E6/E7 RhoC clones had not shown sig-
nificant increase of monolayer growth rate from the
control cells [6]. Interestingly, the monolayer growth
rate assay of the MCF10A-RhoC WT/G14V cells
showed a two-fold increase in proliferating rates com-
pared to the vector-only controls, in three independent
experiments (Figure 3(A)).
Our laboratory had previously established the role
of RhoC in inducing an IBC-like invasive phenotype
in mammary epithelial cells [6]. We examined the new
MCF10A-RhoC clones with a cell invasion assay, con-
taining a Boyden chemotaxis chamber, with the bot-
tom of the insert coated with reconstituted basement
membrane matrix. We confirmed that MCF10A-RhoC
WT exhibited two-fold increase of cell invasion, and
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Figure 2. Fluorescence microscopy of the RhoC transfectants staining with the anti-HA monoclonal antibody (green) to visualize HA-RhoC,
or rhodamine-phalloidin (red) to visualize stress fibers. Cells grown on chamber slides were fixed with 3% paraformaldehyde, permeablized
with 0.1% Triton X-100, and blocked with 1% BSA. The samples were incubated with either the primary anti-HA antibody and the Alexa Fluor
488-conjugated secondary antibody, or rhodamine-phalloidin.
the RhoC G14V cells had three-fold higher invasion
than controls (Figure 3(B)).
Microarray analysis of the MCF10A-RhoC
WT/G14V transfectants
Primary analysis of gene expression in MCF10A-
RhoC WT/G14V, along with MCF10A-vector as con-
trols, was done using the Genepix software package
(Axon Instruments, Union City, CA). Cy5 to Cy3 ra-
tios were determined for the individual genes along
with various other quality control parameters (e.g.,
intensity over local background). Bad spots and de-
fective areas on the array were inspected and manually
flagged. Spots with small diameters (<50 microns)
and spots with low signal strengths <350 fluorescence
intensity units over local background in the more in-
tense channel were also discarded. These data files
were then imported into a Microsoft Access database
and filtered for presence of data points across arrays
and selected for change in expression levels by 2-fold
or more.
SAM analysis [19] was performed by comparing
gene expression profiles of four RhoC overexpressing
clones (two MCF10A-RhoC WT and two MCF10A-
G14V clones) against two RhoC low-expressing
clones. Data were normalized per array by multi-
plication by a factor to adjust the aggregate ratio of
medians to one, then log base two transformed, and
median centered. These normalized data were divided
into two groups for comparison using a two-class, un-
paired t-test. Critical values for the analysis include:
Iterations= 200, random number seed 80842225, a
fold change cutoff of 1.5 and a delta cutoff of 0.598,
resulting in a final largest median false discovery
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Figure 3. The RhoC overexpressing clones exhibit enhanced invasion and proliferation. (A) Quantitative invasion assay. The RhoC WT/G14V
overexpressing cells were resuspended in serum-free medium and seeded in the chemotaxis chamber coated with basement membrane ECM.
Cells penetrating through the artificial basement membranes were stained and resuspended in 10% acetic acid for OD560 readings. (B) Mono-
layer growth rate. RhoC transfectants (500 cells), taken at day 1, 3, 5, 7, 9, and 11, were incubated with MTT, solubilized in DMSO, and
measured absorbance at OD595.
rate of 0.867% for the 115 genes selected as signi-
ficant (108 relatively up- and seven relatively down-
regulated between RhoC overexpressing and RhoC
low-expressing clones).
Overexpression of RhoC WT/G14V significantly
altered message levels of genes involved
in invasion and metastasis
In order to help elucidate the downstream signaling
of RhoC GTPase, we have selected several signifi-
cantly upregulated genes from the microarray results
and examined their mRNA expression by quantitative
RT-PCR. The housekeeping gene GAPDH served as
a loading control (Figure 5(A and B)). We have found
that the message of cyclin D1, a key regulator required
for the G1/S transition in the cell cycle [20] was en-
hanced up to two-fold in the MCF10A-RhoC clones
(Figure 5(A)). Overexpression of RhoC WT/G14V
also increased the expression of two key angiogeneic
factors, VEGF-C [21] and CXCL1 chemokine [22]
(Figure 5(A)). Whereas we observed moderate stim-
ulation of VEGF-C around two-fold, CXC chemokine
ligand 1 (CXCL1) expression was highly enhanced
to seven-fold in the MCF10A-RhoC WT clone com-
pared to the vector-only controls (Figure 5(A)). The
mRNA of Caveolin-2, a protein element of cave-
olar membrane [23], showed two-fold increase in the
MCF10A-RhoC cells (Figure 5(A)). Notably as well,
RhoC has a significant effect on the message level of
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fibronectin, a major component of connective-tissue
type of ECM [24] (Figure 5(A)). Both alternatively
spliced transcripts of fibronectin [25] were tested and
they were equivalently upregulated. Fibronectin and
CXCL1 are the two most upregulated genes identified
in the array analysis.
On the other hand, we have found that RhoC over-
expression decreased the message level of IGFBP-2, a
high-affinity IGF binding protein. IGFBP2 is known
to function as an inhibitor of IGF, a potent mitogen of
breast cancer cells [26]. The mRNA of IGFBP-2 in the
MCF10A-RhoC WT and MCF10A-G14V clones was
lowered for 70 and 50%, respectively (Figure 5(B))
which correlated with and confirmed the array data.
This result further supports the role of RhoC in en-
hancing tumor aggressiveness and perhaps enabling
enhanced IGF signaling.
Discussion
In this study, we summarize our initial work to ex-
plore the molecular basis for RhoC-induced invasive
phenotype in spontaneous immortalized breast cells
(MCF10A) using RNA microarray techniques. We
have focused our validation experiments on five upreg-
ulated gene products involved in cell cycle progression
(cyclin D1), angiogenesis (VEGF-C and CXCL1), and
cell adhesion (fibronectin), and one down-regulated
gene (IGFBP2).
Cyclin D1 is essential for G1 cell cycle progression
and its expression is significantly higher in a variety of
tumors, notably breast, parathyroid and sarcomas [27].
Inhibition of Rho, as well as Rac and Cdc42, can
arrest the cell cycle at G1 [24]. Rac and Cdc42 sig-
naling activate JNK and p38, which in turn stimulate
cyclin D1 expression [28]. Conversely, activation of
RhoA, a protein highly homologous to RhoC, stimu-
lates transcription of AP-1, a major transcription factor
controlling the cyclin D1 promoter [28]. Cyclin D1
transcription is also induced by the integrin-ECM sig-
naling pathway [24]. Interactions between fibronectin
and integrin activate focal adhesion kinase (FAK),
which, in turn, transmits the signal to Rac and induces
cyclin D1 transcription [24]. We have observed signi-
ficant upregulation of fibronectin in our RhoC clones
(Figure 5(A)). Therefore, increased cyclin D1 message
in RhoC overexpressed breast cells may arise from
the concerted effect of RhoC and Rac/Cdc42 signal-
ing or possibly by the effects of fibronectin-dependent
integrin activation.
VEGF-C, a member of the vascular endothelial
growth factor family, is crucial for new capillary
growth from existing vessels [21]. VEGF-C binds
with high affinity to the VEGF receptor 3 (VEGFR3),
but it also binds to VEGFR2 with low affinity [21].
VEGF/VEGFR signaling is essential for endothelial
cell proliferation, chemotaxis, and vascular per-
meability. Mice carrying a VEGFR2 deletion did
not have differentiated blood vessels or capillaries,
whereas VEGFR3 knockout mice showed no defects
in angiogenesis, but had abnormal vessel permeab-
ility causing fluid accumulation [21]. In previous
work [29], we showed that RhoC activation induces
angiogenesis, likely through p38 signaling. Now we
show that the VEGF-C is specifically upregulated by
RhoC activation, suggesting a possible role of RhoC
also in promoting lymphagiogenesis.
CXCL1 is also known as melanoma growth reg-
ulated protein (GRO), as it was first identified from
human melanoma conditioned medium [22]. CXC
chemokines are heparin-binding proteins with two
conserved cysteines flanking one other residue. The N-
terminus of many family members (termed as ELR+)
contains the ELR motif (Glu–Leu–Arg). The ELR+
chemokines, including CXCL1, are highly effective
in promoting angiogenesis in physiological concen-
tration of 1–100 Nm [30]. In melanoma, uncontrolled
increases of CXCL1 or CXCL8 chemokines lead
to angiogenesis and tumorigenesis, with concomi-
tant constitutively activation of NF-kB. These CXCL-
overexpressed melanoma cells also become greatly
metastatic [22].
Fibronectin is a major component of stromal
matrices, which are found at sites of injury and inflam-
mation. Cell adhesion to this type of matrices often
leads to migration and proliferation, instead of growth
arrest and differentiation as occurs in contact with the
basement membrane-type of ECM [31]. Transcrip-
tion of fibronectin is stimulated by cAMP (forskolin)
and TGF-β [32]. TGF-β, a potent regulator for cell
growth, activates RhoA-dependent signaling and me-
diates the epithelial-mesenchymal transition and stress
fiber formation [33, 34]. In addition, expression of
NET1, a Rho GEF, is induced by TGF-β [35]. In con-
trast, cAMP activates cAMP-dependent kinase (PKA),
which phosphorylates and inhibits RhoA [36]. Taken
together based on these data, we propose that RhoC
overexpression may help enhance TGF-β signaling
thereby enhancing fibronectin expression.
Our results also indicate that caveolin-2 is up-
regulated in the RhoC overexpressing breast cells
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Figure 4. SAM analysis plot obtained by comparing gene expression profiles of two MCF10A-RhoC WT and two MCF10A-G14V clones
against two RhoC low-expressing clones showing 108 genes as relatively up- and seven genes as relatively down-regulated at a false discovery
rate of 0.867%. Each spot on the plot represents one gene on the chip. The spots enclosed by the diagonal lines represent unchanged gene
expression levels; the genes falling out of that range on the +ve plane are up-regulated (shown as red circles), and the genes falling out of that
range on the −ve plane are down-regulated (shown as green triangles).
(Figure 5(A)). Caveolins are major structural proteins
of caveolae, which are plasma membrane invagina-
tions found in many cell types, including fibroblasts,
epithelial cells and endothelial cells [37]. These mem-
brane ruffles support and concentrate growth factor
receptors and their immediate downstream signaling.
The caveolin gene family consists of three members,
caveolin-1, -2, and -3. Caveolin-1 is known to form
homodimers or heterodimers with caveolin-2 in ca-
veolae biosynthesis [37]. The function of caveolin-2
in human cancer is very poorly understood, com-
pared to the family member caveolin-1. The caveolin-
1 gene is frequently deleted in human chromosome
in a plethora of cancers, including squamous cell
carcinomas, ovarian adenocarcinomas, prostate and
breast cancers [37]. Down-regulation of caveolin-1 is
also known as a feature of terminally differentiated
cells [38]. Furthermore, the molecular mechanism
of caveolin-1 as a tumor suppressor was to inhibit
Neu tyrosine kinase pathway [39]. Overexpression of
caveolin-1 inhibited the Neu pathway, and reduced
tumor size in Neu-expressing transgenic mice. Inter-
estingly, oncogenic activation of Neu down-regulated
caveolin-1, but not caveolin-2 [39]. Since we have ob-
served moderate increase of caveolin-2 in MCF10A-
RhoC, highly invasive breast cells (Figure 5(A)), it
would be interesting to explore whether caveolin-
2 serves a specific role in tumorigenesis in this
system.
In our array expression experiments, we have
found 108 upregulated genes and only seven down-
regulated genes when we compared the MCF10A-
RhoC WT/G14V clones with MCF10A-Vector and
RhoC low-expressing cells (Figure 4). We identi-
fied IGFBP-2 message levels to be lowered in both
WT and G14V transfectants using quantitative RT-
PCR (Figure 5(B)). IGFBP2 is a negative regulator
of the IGF system. IGF (insulin-like growth factors)
are important mediators of cell growth and develop-
ment. They are synthesized by nearly all tissues in
the body and their functions are regulated by receptor
tyrosine kinases in a complex circuitry of signaling.
In breast cell carcinogenesis, IGF-1 increases can-
cer cell proliferation through two mechanisms. IGF-
1 enhances cancer cell growth and also promotes
stromal cell outgrowth in a paracrine or autocrine
manner [26]. IGFBP3, also a high-affinity inhibitor
to IGFs, repressed IGF signaling in breast cancer
cells even without physical interactions with IGF [40].
Furthermore, WISP3/LIBC, a tumor suppressor first
identified in our laboratory, was predicted as a member
of IGFBP-rPs by its protein sequence [5]. IGFBP-rP
proteins show relatively low affinity for IGF binding
so they may regulate cell growth by mechanisms other
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Figure 5. Quantitative RT-PCR analysis of the RhoC clones. Se-
quence-specific primer pairs were designed to amplify cyclin D1,
caveolin-2, VEGF-C, fibronectin, CXCL1, and IGFBP2 (the mRNA
sequences of the above genes were downloaded from Genbank,
NCBI, NIH). In the RT-PCR reaction, 100 mg of cDNA was ampli-
fied with 25 ng each of the primers. The products were separated on
a 1.2% agarose gel. GAPDH was served as a loading control.
than direct binding to IGF. IGFBP-rP1 was also pro-
posed to be a potential tumor suppressor protein for
prostate cancer [26]. In conclusion, down-regulation
of IGFBP2 by RhoC supports that RhoC overexpres-
sion may enhance an IBC-like, invasive phenotype
in normal breast cells by modulation of IGF signal-
ing. Taken together, our data present a number of key
molecules that are likely to be involved in the phen-
otype changes induced by RhoC, suggesting future
investigations in this area.
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